These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36709123)

  • 1. [Single-center study of different treatment for advanced or unresectable angiosarcoma patients].
    Peng RQ; Xu BS; Liu YY; Yang QQ; Pan QZ; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):74-81. PubMed ID: 36709123
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
    Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
    J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
    Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
    Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
    Park C; Kim M; Kwak Y; Moon KC; Kim SH; Keam B; Kim YJ; Kim TM; Kim DW
    Cancer Res Treat; 2021 Oct; 53(4):1195-1203. PubMed ID: 33540493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.
    Fury MG; Antonescu CR; Van Zee KJ; Brennan MF; Maki RG
    Cancer J; 2005; 11(3):241-7. PubMed ID: 16053668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
    Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
    Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium.
    Chen TW; Pang A; Puhaindran ME; Maw MM; Loong HH; Sriuranpong V; Chang CC; Mingmalairak S; Hirose T; Endo M; Kawai A; Farid M; Tan SH; Goh WL; Quek R; Chan JCH; Leung AKC; Ngan RKC
    Cancer Sci; 2021 Mar; 112(3):1095-1104. PubMed ID: 33393133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Zhao L; Zhao Z; Yan X; Wu F; Sun N; Guo R; Yu S; Hu X; Feng J
    Int J Clin Pract; 2024; 2024():8585035. PubMed ID: 38375028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].
    Sun CX; Wang SS; Li JB; Wang YS; Ouyang QC; Yang J; Wang HB; Wang XJ; Chen WY; Yuan P; Yan M; Jiang ZF; Yin YM
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):88-94. PubMed ID: 36709125
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
    Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
    Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.
    Skubitz KM; Haddad PA
    Cancer; 2005 Jul; 104(2):361-6. PubMed ID: 15948172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Observation of Immunotherapy Efficacy and Adverse Effects 
in Chinese Patients with Lung Squamous Cell Carcinoma].
    Yu J; Wu X; Ma J; Chen X; Li L
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):546-554. PubMed ID: 35899455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
    Jones RL; Ravi V; Brohl AS; Chawla S; Ganjoo KN; Italiano A; Attia S; Burgess MA; Thornton K; Cranmer LD; Cheang MCU; Liu L; Robertson L; Adams B; Theuer C; Maki RG
    JAMA Oncol; 2022 May; 8(5):740-747. PubMed ID: 35357396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.
    Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1251258. PubMed ID: 37810973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
    Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
    Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
    Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.